Handelsbanken Fonder AB Has $24.59 Million Stock Position in Becton, Dickinson and Company $BDX

Handelsbanken Fonder AB cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 131,389 shares of the medical instruments supplier’s stock after selling 4,040 shares during the quarter. Handelsbanken Fonder AB’s holdings in Becton, Dickinson and Company were worth $24,592,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BDX. Brighton Jones LLC grew its holdings in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. Empowered Funds LLC boosted its position in Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after buying an additional 1,354 shares during the period. United Bank raised its stake in shares of Becton, Dickinson and Company by 23.9% during the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock valued at $887,000 after acquiring an additional 993 shares during the last quarter. Arkadios Wealth Advisors raised its position in Becton, Dickinson and Company by 12.6% during the 2nd quarter. Arkadios Wealth Advisors now owns 5,677 shares of the medical instruments supplier’s stock worth $978,000 after purchasing an additional 634 shares during the last quarter. Finally, Savvy Advisors Inc. increased its stake in shares of Becton, Dickinson and Company by 16.5% in the second quarter. Savvy Advisors Inc. now owns 1,375 shares of the medical instruments supplier’s stock valued at $237,000 after buying an additional 195 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $176.04 on Friday. The company has a market cap of $50.12 billion, a P/E ratio of 28.72, a PEG ratio of 12.79 and a beta of 0.25. The company has a fifty day simple moving average of $195.68 and a 200 day simple moving average of $192.06. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period last year, the firm earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. Becton, Dickinson and Company’s payout ratio is 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share buyback program on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BDX. Wells Fargo & Company cut their price objective on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 10th. Piper Sandler restated a “neutral” rating and set a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. JPMorgan Chase & Co. cut their price target on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. Citigroup dropped their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Finally, Royal Bank Of Canada set a $172.00 target price on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and an average price target of $195.46.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director directly owned 36,763 shares of the company’s stock, valued at $6,713,291.43. The trade was a 2.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,491 shares of company stock worth $689,195 in the last 90 days. Corporate insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.